CRC, effect of cannabinoids in animal models

Disease modelTreatmentComparatorResultsRef.
Colon cancer induced by AOM in ICR miceCBD 1 mg/kg or 5 mg/kg, i.p., 3 times per week, over 4 weeksvs. controlCBD, starting 1 week before the first administration of AOM, reduced significantly ACF, polyps and tumour formation (40% of mice with tumours after 1 mg/kg compared to 70% after 5 mg/kg)[82]
Colon cancer induced by AOM in miceCBG 1 or 5 mg/kg i.p. 3 times per week, 4 weeksAOM only (10 mg/kg i.p.) once weeklyCBG (1 mg/kg) treatment reduced the number of ACF; at the 5 mg/kg dose, CBG completely suppressed the formation of ACF, and reduced by one half the number of tumours[31]
Colorectal carcinoma HCT 116 cells, xenograft, nude miceCBG 1, 3, or 10 mg/kg i.p. every day for 5 daysVehicle without CBGAfter 5 days, the average tumour volume in the control group was 2,500 mm3, in the CBG 3 mg/kg group 1,367 mm3 (45.3% inhibition of tumour growth); CBG 10 mg/kg did not increase the effect; dose dependency: 1 < 3 ~10 mg/kg per day[31]
Colon cancer induced by AOM in miceCBD-E 5 mg/kg, i.p., 3 times per week up to 3 months after 1st injection of AOMvs. controlsCBD-E reduced AOM-induced pre-neoplastic lesions and polyps (inhibition AOM-induced ACF by 86%, polyps by 79%) and tumour growth (by 40%)[83]
Human epithelial colon adenocarcinoma cells (HCT 116), s.c. xenograft, ICR miceCBD-E 5 mg/kg per day, i.p., for 7 daysvs. control

CBD-E ≃ control;

Tumour growth between control and CBD-E was signif. different on day 4, but no difference on day 7

[83]

AOM: azoxymethane; ACF: aberrant crypt foci; signif.: significant; CBD-E: CBD-extract (synonym: CBD-BDS, CBD botanical drug substance); ≃: almost equal; ~: about